Abstract
Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice. A number of these patients may be refractory to peripherally acting agents, yet respond to central neuromodulators. There are benefits and potential adverse effects to using TCAs, SSRIs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients. These agents can benefit mood, pain, diarrhea, constipation, nausea, sleep, and depression. The mechanisms by which they work, the differences between classes and individual agents, and the various adverse effects are outlined. Dosing, augmentation strategies, and treatment scenarios specifically for painful FGIDs, FD with PDS, and chronic nausea and vomiting syndrome are outlined.
MeSH terms
-
Antidepressive Agents, Tricyclic / pharmacology
-
Antidepressive Agents, Tricyclic / therapeutic use*
-
Antipsychotic Agents / therapeutic use
-
Clinical Competence
-
Defecation / drug effects
-
Gastrointestinal Diseases / drug therapy*
-
Gastrointestinal Hemorrhage / chemically induced
-
Humans
-
Nausea / chemically induced
-
Nausea / drug therapy
-
Neurotransmitter Agents / pharmacology
-
Neurotransmitter Agents / therapeutic use*
-
Selective Serotonin Reuptake Inhibitors / pharmacology
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Serotonin Syndrome / chemically induced
-
Serotonin and Noradrenaline Reuptake Inhibitors / pharmacology
-
Serotonin and Noradrenaline Reuptake Inhibitors / therapeutic use
-
Sexual Dysfunction, Physiological / chemically induced
-
Vomiting / chemically induced
Substances
-
Antidepressive Agents, Tricyclic
-
Antipsychotic Agents
-
Neurotransmitter Agents
-
Serotonin Uptake Inhibitors
-
Serotonin and Noradrenaline Reuptake Inhibitors